GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.50 USD
+0.15 (0.35%)
Updated May 3, 2024 04:00 PM ET
After-Market: $43.50 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Price, Consensus and EPS Surprise
GSK 43.50 +0.15(0.35%)
Will GSK be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for GSK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GSK
Why GSK (GSK) is a Top Growth Stock for the Long-Term
Why GSK (GSK) is a Top Growth Stock for the Long-Term
GSK: What are Zacks experts saying now?
Zacks Private Portfolio Services
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
Other News for GSK
Pharma R&D productivity seen improving for the first time in years - Deloitte
Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders
GSK plc (GSK) Q1 2024 Earnings Call Transcript
GSK Executive Sells Shares on London Exchange
June 14th Options Now Available For GSK